ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a multinational healthcare company, for the development and commercialization of ADEL-Y01, a potential first-in-class antibody therapy for Alzheimer's disease, and related backup compounds.